STRATA Skin Sciences Announces Approval of XTRAC Momentum™ 1.0 Device in Japan
July 22 2024 - 8:00AM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ:
SSKN), a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
treatment of dermatologic conditions, announces the approval of its
XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and
Welfare of Japan. The Company initially launched the XTRAC
Momentum™ in the U.S. in early 2022. The immediate commercial
rollout of the device in Japan will be through JMEC Co., Ltd., the
Company’s longstanding Japanese strategic partner and distributor.
STRATA’s excimer devices are currently used by over 300 hospitals
and private practice dermatology clinics in Japan.
“With this regulatory approval, we are now able
to offer the Momentum™ device -- our most advanced excimer laser --
into the Japanese dermatology market. Working with JMEC, we look
forward to introducing doctors and patients to the benefits of
Momentum™ for the treatment of various dermatology conditions, such
as psoriasis, eczema, and vitiligo,” commented STRATA’s President
and CEO Dr. Dolev Rafaeli.
The Company’s XTRAC® excimer laser technology
allows for the precise delivery of targeted UVB light therapy to
specific treatment areas of the skin, for both adult and pediatric
patients suffering from inflammatory skin conditions such as
psoriasis, atopic dermatitis, and vitiligo. The new XTRAC Momentum™
1.0 represents the latest in excimer laser technology and delivers
higher power and a faster repetition rate than the current models.
The Momentum™ also offers a new user interface and slim design,
both intended to improve the treatment experience.
About STRATA Skin Sciences
STRATA Skin Sciences is a medical technology
company dedicated to developing, commercializing, and marketing
innovative products for the in-office treatment of various
dermatologic conditions, such as psoriasis, vitiligo, and acne. Its
products include the XTRAC® excimer laser, VTRAC® lamp
systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership Program.
STRATA’s popular partnership approach includes a fee per treatment
cost structure (versus an equipment purchase), installation and use
of the device, on-site training for practice personnel, service and
maintenance of the equipment, dedicated account and customer
service associates, and co-op advertising support to help raise
awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking
statements" within the meaning of the Securities Litigation Reform
Act of 1995. These statements include but are not limited to the
Company’s plans, objectives, expectations and intentions and may
contain words such as “will,” “may,” “seeks,” and “expects,” that
suggest future events or trends. These statements, the Company’s
ability to launch and sell products recently acquired or to be
developed in the future, the Company’s ability to develop social
media marketing campaigns, direct to consumer marketing campaigns,
and the Company’s ability to build a leading franchise in
dermatology and aesthetics, are based on the Company’s current
expectations and are inherently subject to significant
uncertainties and changes in circumstances. Actual results may
differ materially from the Company’s expectations due to financial,
economic, business, competitive, market, regulatory, adverse market
conditions labor supply shortages, or supply chain interruptions
resulting from fiscal, political factors, international conflicts,
responses, or conditions affecting the Company, the medical device
industry and our customers and patients in general, as well as more
specific risks and uncertainties set forth in the Company’s SEC
reports on Forms 10-Q and 10-K. Given such uncertainties, any or
all these forward-looking statements may prove to be incorrect or
unreliable. The statements in this press release are made as of the
date of this press release, even if subsequently made available by
the Company on its website or otherwise. The Company does not
undertake any obligation to update or revise these statements to
reflect events or circumstances occurring after the date of this
press release. The Company urges investors to carefully review its
SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:CORE
IR516-222-2560IR@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2023 to Aug 2024